Lupin: USFDA approval adds a positive trigger

is in focus after receiving USFDA approval for Modafinil Tablets USP 100 mg and 200 mg. The drug is bioequivalent to Provigil and is used to improve wakefulness in adults suffering from excessive sleepiness linked to narcolepsy, obstructive sleep apnea and shift-work disorder. The approval strengthens Lupin’s U.S. generics portfolio and provides another product opportunity in its CNS segment. The reference product, Provigil, had estimated U.S. annual sales of $70.7 million as of July 2026, indicating a meaningful addressable market, although actual revenue potential for Lupin will depend on pricing, competition and market share. The stock closed at ₹2,111 on September 4, down 1.12%, and remains about 16.6% below its 52-week high of ₹2,530. Investor takeaway: The approval is a positive near-term catalyst for Lupin, but investors should monitor the product’s commercial launch, competitive intensity and U.S. pricing before assuming a significant earnings impact.